Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 28, 2019

FDA approves SK Chemicals’ dementia treatment patch

The US Food and Drug Administration (FDA) has approved South Korean company SK Chemicals’ patch-type Alzheimer's drug, SID710.

The US Food and Drug Administration (FDA) has approved South Korean company SK Chemicals’ patch-type Alzheimer’s drug, SID710.

SID710, which has already secured approval in the European Union in 2013, is the generic version of Novartis’ Exelon Patch for the treatment of dementia symptoms associated with Alzheimer’s disease.

The latest approval marks the first time a South Korean pharmaceutical company has applied to the US regulator for an Alzheimer’s patch on its own and secured it.

SK Chemicals CEO Jeon Kwang-hyun said: “It is meaningful that SK Chemicals’ high technology skill was acknowledged through the FDA approval.”

Kwang-hyun added that the company are aiming to distribute the product into the South American and Southeast Asian markets.

SID710, currently being sold in 19 countries including Australia and Canada, was developed independently by SK Chemicals in 2010.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The drug, which contains rivastigmine, supports patients with Alzheimer’s disease who mostly fail to take their medicine and face difficulties in swallowing tablets to attach the patch on the skin once a day for continuous delivery to the body.

Patients should use the patch only once a day. However, the drug’s efficacy is similar to other oral medications.

The treatment has been sold in Korea under the brand Wondron patch since 2014.

Since the establishment of Sunkyung Textiles in 1969, SK chemicals has expanded into a chemical and life sciences enterprise representing South Korea.

The company’s life sciences business is dominated by pharmaceuticals and bio. It is anchored by healthcare solutions that cover patient care from diagnosis to treatment and prevention.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy